Skip to main content

Neurogene Inc 10-Q for FY2026 Q3

Neurogene Inc. (NGNE)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Neurogene Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Neurogene Inc. completed dosing 25 participants in the Embolden registrational trial for NGN-401, expects topline results in the second half of 2027, and expects cash, cash equivalents and investments to fund operations into the first quarter of 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$29.02M
compared with a net loss of $20.95M a year earlier
Diluted EPS
-$1.05
compared with -$0.99 a year earlier